Summary
The present study assessed changes of tryptamine, dopamine D2, 5-HT1 and 5-HT2 binding sites in rat brain following chronic treatment with low (5 mg/kg/day) and high (40 mg/kg/day) doses of molindone, a clinically effective psychotropic drug. The high-dose molindone treatment produced a decrease in the number of tryptamine binding sites while both high and low doses caused an increase in the number of dopamine D2 binding sites in the striatum. No significant changes were observed in either 5-HT1 or 5-HT2 binding sites in the cerebral cortex. Competition binding experiments showed that molindone was a potent inhibitor at dopamine D2 but less effective at tryptamine, 5-FT1 and 5-HT2 binding sites. The inhibition activity of molindone towards type A monoamine oxidase produced a significant increase in endogenous tryptamine accumulation rate which was much higher than that of dopamine and 5-HT. These findings suggest that the reduction in the number of tryptamine binding sites produced by chronic molindone administration is related to monoamine oxidase inhibition and that the increase in the number of dopamine D2 binding sites is correlated to receptor blocking activity of the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altar CA, Wasley AM, Martin LL (1986) Autoradiographic localization and pharmacology of unique [3H]tryptamine binding sites in rat brain. Neuroscience 17:263–273.
Ayd FJ (1974) A critical evaluation of molindone (Moban): A new indole derivative neuroleptic. Dis Nervous Syst 35:447–452.
Bruning G, Rommelspacher H (1984) High affinity [3H]tryptamine binding sites in various organs of the rat. Life Sci 34:1441–1446.
Burt DR, Enna SJ, Creese I, Snyder SH (1975) Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci [USA] 72:4655–4659.
Creese I, Sibley DA (1981) Receptor adaptation to centrally acting drugs. Annual Rev Pharmacol and Toxicol 21:357–391.
Creese I, Stewart K, Snyder SH (1979) Species variations in dopamine receptor binding. Eur J Pharmacol 60:55–66.
Durden DA, Philips SE (1980) Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain. J Neurochem 34:1725–1732.
Graham D, Langer SZ (1987) [3H]Tryptamine binding sites of rat cerebral cortex: Pharmacological profile and plasticity. Neuropharmacology 26:1093–1097.
Greenshaw AJ, Dewhurst WG (1987) Tryptamine receptors: Fact, myth or misunderstanding? Brain Res Bull 18:253–256.
Jones RSJ (1982) Tryptamine: A neuromodulator or neurotransmitter in mammalian brain? Progr Neurobiol 19:117–139.
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1447–1454.
Juorio AV (1980) Effects of molindone and fluphenazine on the brain concentration of some phenolic and catecholic amines in the mouse and the rat. Br J Pharmacol 70:475–480.
Juorio AV, Greenshaw AJ (1986) Tryptamine depletion in the rat striatum following electrolytic lesions of the substantia nigra. Brain Res 371:385–389.
Juorio AV, Greenshaw AJ, Nguyen TV (1987) Effect of intranigral administration of 6-hydroxytryptamine on rat brain tryptamine. J Neurochem 48:1346–1350.
Kaulen P, Bruning G, Rommelspacher H, Baumgarten HG (1986) Characterization and quantitative autoradiography of [3H]-tryptamine binding sites in rat brain. Brain Res 366:72–88.
Kellar KJ, Cascio CS (1982) [3H]Tryptamine: High affinity binding sites in rat brain. Eur J Pharmacol 78:475–478.
Koe BK (1979) Biochemical assessment of the neuroleptic activity of molindone. In: Usdin E, Kopin IJ, Barchas JD (eds) Catecholamines: Basic and clinical frontiers, vol 1. Pergamon Press, Oxford, pp 740–742.
Kwok RPS, Juorio AV (1986) The concentration of striatal tyramine and dopamine metabolism in diabetic rats and the effect of insulin administration. Neuroendocrinology 43:590–596.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
Martin LL, Neale RF, Wood PL (1987) Down-regulation of tryptamine receptors following chronic administration of clorgyline. Brain Res 419:239–243.
Martin LL, Roland DM, Neale RF, Wood PL (1986) Structural relationships in the inhibition of [3H]tryptamine binding to rat brain membranes in vitro by phenylethylamine. Eur J Pharmacol 132:53–55.
McPherson GA (1983) A practical computer-base approach to the analysis of radioligand bonding experiment. Comp Programs Biomed 17:220–239.
Meller E, Friedman E (1982) Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: Mediation by irreversible inhibition of monoamine oxidase. J Pharmacol Exp Ther 220:609–615.
Munson PJ, Rodbard D (1980) LIGAND: A versatile computerized approach for characterization of ligand binding systems. Anal Biomed 107:220–239.
Nguyen TV, Juorio AV (1989) Binding sites for brain trace amines. Cell Mol Neurobiol 9:297–311.
Nguyen TV, Paterson IA, Juorio AV, Greenshaw AJ, Boulton AA (1989) Tryptamine receptors: Neurochemical and electrophysiological evidence for postsynaptic and functional binding sites. Brain Res 476:85–93.
Overstreet DH, Yamamura HI (1979) Receptor alterations and drug tolerance. Life Sci 25:1856–1878.
Perry DC (1986) [3H]Tryptamine autoradiography in rat brain and choroid plexus reveals two distinct sites. J Pharmacol Exp Ther 236:548–559.
Philips SR, Boulton AA (1979) The effects of monoamine oxidase inhibitors on some aryl alkylamines in rat striatum. J Neurochem 33:159–167.
Philips SR, Durden DA, Boulton AA (1974) Identification and distribution of tryptamine in the rat. Can J Biochem 52:447–451.
Robinson SE, Berney S, Mishra R, Sulser F (1979) The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: Metoclopramide, thiethylperazine, and molindone as pharmacological tools. Psychopharmacology 64:141–147.
Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Nat Acad Sci [USA] 72:4376–4380.
Wood PL, Pilapil C, LaFaille F, Nair PV, Glennon RA (1984) Unique [3H]tryptamine binding sites in rat brain: Distribution and pharmacology. Arch Int Pharmacodyn 268:194–201.
Wurtman RJ, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 72:439–441.
Yu PH (1985) Some aspects of the oxidative deamination of tryptamine by MAO-A and MAO-B in different tissues. In: Boulton AA, Maitre L, Bieck PR, Riederer P (eds) Neuropsychopharmacology of the trace amines. Humana Press, New Jersey, pp 301–308.
Author information
Authors and Affiliations
Additional information
Send offprint requests to A. V. Juorio at the above address
Rights and permissions
About this article
Cite this article
Van Nguyen, T., Juorio, A.V. Down-regulation of tryptamine binding sitess following chronic molindone administration. Naunyn-Schmiedeberg's Arch Pharmacol 340, 366–371 (1989). https://doi.org/10.1007/BF00167036
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00167036